All In Biotech

Drug Trial Radar · NCT02120950

Aflibercept in Polypoidal Choroidal Vasculopathy

A Randomized, Double-masked, Sham-controlled Phase 3b/4 Study of the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Monotherapy Compared to Aflibercept With Adjunctive Photodynamic Therapy as Indicated in Subjects With Polypoidal Choroidal Vasculopathy

Last checked: Nov 20, 2026Latest source record: Dec 2, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 333 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

333

Actual

Start

May 29, 2014

Primary completion

Aug 12, 2016

Study completion Jul 7, 2017

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
Collaborators
Regeneron Pharmaceuticals
First posted
Apr 23, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To collect data reflecting the efficacy and safety of aflibercept with and without photodynamic therapy in subjects diagnosed with the polypoidal choroidal vasculopathy subtype of wet age-related macular degeneration

Conditions

  • Neovascular Macular Degeneration

Interventions

  • Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)Drug

    Eylea is administered as an intravitreal injection

  • VisudyneOther

    Photodynamic therapy is a combined therapy of drug (Visudyne) applied to reinforce the action of a device (laser)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Change in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment of Diabetic Retinopathy Study (ETDRS) Letter Scores From Baseline to Week 52 - Last Observation Carried Forward (LOCF)Time frame: From Baseline to Week 52

Locations

62 sites in 8 countries. Site status is shown where the registry gives one.

  • Site not named

    Parramatta, Australia

  • Site not named

    Liverpool, New South Wales, Australia

  • Site not named

    Strathfield, New South Wales, Australia

  • Site not named

    Westmead, New South Wales, Australia

  • Site not named

    East Melbourne, Victoria, Australia

  • Site not named

    München, Germany

  • Site not named

    Hong Kong, Hong Kong

  • Site not named

    Kowloon, Hong Kong

  • Site not named

    Budapest, Hungary

  • Site not named

    Budapest, Hungary

  • Site not named

    Budapest, Hungary

  • Site not named

    Debrecen, Hungary

  • Site not named

    Akita, Japan

  • Site not named

    Aomori, Japan

  • Site not named

    Chiba, Japan

  • Site not named

    Fukuoka, Japan

  • Site not named

    Fukuoka, Japan

  • Site not named

    Fukushima, Japan

  • Site not named

    Kumamoto, Japan

  • Site not named

    Kyoto, Japan

  • Site not named

    Kyoto, Japan

  • Site not named

    Nagasaki, Japan

  • Site not named

    Okayama, Japan

  • Site not named

    Osaka, Japan

  • Site not named

    Tokushima, Japan

  • Site not named

    Wakayama, Japan

  • Site not named

    Nagoya, Aichi-ken, Japan

  • Site not named

    Urayasu, Chiba, Japan

  • Site not named

    Ōgaki, Gifu, Japan

  • Site not named

    Maebashi, Gunma, Japan

  • Site not named

    Asahikawa, Hokkaido, Japan

  • Site not named

    Sapporo, Hokkaido, Japan

  • Site not named

    Amagasaki, Hyōgo, Japan

  • Site not named

    Kobe, Hyōgo, Japan

  • Site not named

    Kita, Kagawa-ken, Japan

  • Site not named

    Tsu, Mie-ken, Japan

  • Site not named

    Kashihara, Nara, Japan

  • Site not named

    Hirakata, Osaka, Japan

  • Site not named

    Suita, Osaka, Japan

  • Site not named

    Ōtsu, Shiga, Japan

Showing 40 of 62 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.